Copenhagen, October 2024 – Interlinked AB recently had the honor of participating in the LSX Nordic Congress 2024, a leading event for life science executives, investors, and innovators across the Nordic region. The congress, hosted in Copenhagen, provided a dynamic platform for insightful discussions and potential collaborations aimed at shaping the future of healthcare.
Our CEO, Katarina Hedbeck, represented Interlinked AB on a distinguished panel discussion, joined by Kim Baden-Kristensen (Brain+), Thomas Lethenborg (Monsenso), and Jeremy McCrohan (Uncommon). The panel explored the key question, “When is the right time to begin commercialization?” Reflecting on the session, Hedbeck remarked, "It was a pleasure to be on the panel with such thought leaders, diving into one of the most critical decisions in any healthcare company’s journey."
The congress provided invaluable opportunities for knowledge exchange and networking with leading minds in healthcare innovation. The presence of Interlinked AB further strengthened our mission to revolutionize patient safety and healthcare efficiency through cutting-edge solutions, particularly our breakthrough product, ReLink, designed to prevent catheter dislodgement in IV therapy and nephrostomy drainage.
Our team left Copenhagen inspired and enthusiastic about the collaborations and possibilities discussed. As we continue to push the boundaries of medical technology, we are committed to forming meaningful partnerships that drive impactful solutions across the healthcare sector.
Comments